Gestational trophoblastic tumors and tumor-like lesions can be confused with a variety of nontrophoblastic tumors. 14, 15 The distinction is important, as the management and treatment of trophoblastic and nontrophoblastic tumors are vastly different. Although other trophoblastic markers such as ␤-human chorionic gonadotropin (hCG), human placental lactogen (hPL), Mel-CAM, PlAP and inhibin-␣ have proved to be useful in the differential diagnosis of trophoblastic lesions, none is ideal because of either lack of adequate specificity or sensitivity. Because all of these trophoblastic lesions are composed of intermediate trophoblast (IT), albeit different types, i.e., implantation site or chorionic-type IT, immunohistochemistry using an IT-specific marker on paraffin tissues would be very useful in their differential diagnosis.
Human leukocyte antigens (HLAs) are cell surface proteins expressed in immune cells and are important determinants of alloreactivity. 5 HLA-G is a nonclassical MHC class I antigen that interacts with natural killer cells, can present nonamer peptides, and bind CD8 in an analogous manner to classic HLA class I proteins. 21 Furthermore, HLA-G has been shown to be important for the escape of immunosurveillance (alloreactivity) by host T lymphocytes and NK cells. 5 In normal and molar placentas, expression of HLA-G and other HLA molecules is thought to play a role in maternal tolerance toward fetal tissue. HLA-G isoforms have been demonstrated in populations of IT cells in both normal and molar placentas as well as in JEG-3, a choriocarcinoma cell line. 1, 3, 8 In view of what appears to be exclusive expression of HLA-G in IT cell populations of normal and molar placentas and its highly restricted expression in other tissues, we postulated that the expression of HLA-G would be maintained in lesions derived from IT and therefore that HLA-G immunoreactivity could be a specific marker for them.
In this study we investigated the immunoreactivity of an HLA-G antibody, 4H84, which recognizes all known HLA-G isoforms in a variety of gestational trophoblastic lesions and a wide range of common uterine neoplasms to assess its utility for the differential diagnosis of gestational trophoblastic lesions. Complete and partial moles were not studied because expression of HLA-G in molar placentas has been previously reported, 3 and the distinction of nontrophoblastic tumors from molar placentas is not a problem.
MATERIALS AND METHODS

Tissue Samples
Formalin-fixed, paraffin-embedded tissue blocks from 10 normal first trimester placentas, 66 gestational trophoblastic lesions, and 34 miscellaneous nontrophoblastic uterine neoplasms were retrieved from the archival files of the Gestational Trophoblastic Disease Tissue Bank and the Surgical Pathology files of the Johns Hopkins Hospital. Most of the trophoblastic lesions were sent in consultation to one of the authors (R.J.K.). These trophoblastic lesions included 14 choriocarcinomas, 14 placental site trophoblastic tumors, 13 epithelioid trophoblastic tumors, 16 placental site nodules, and nine exaggerated placental sites. The nontrophoblastic uterine tumors included 10 invasive cervical squamous cell carcinomas, nine poorly differentiated endometrial carcinomas, nine low-grade endometrial stromal sarcomas, one malignant mixed mesodermal tumor, one typical leiomyosarcoma, one epithelioid leiomyosarcoma, one typical leiomyoma, and two epithelioid leiomyomas.
Immunohistochemistry
After deparaffinization, tissue sections (5 m) were steamed in a citrate buffer for 5 minutes to facilitate antigen retrieval. The slides were then incubated with the supernatant of the 4H84 monoclonal antibody (IgG1, provided by Michael M. McMaster, 1:600) 5 using the avidin-biotin peroxidase method. The reaction product was visualized with 3,3Ј-diaminobenzidine chromagen and the sections counterstained with 0.1% hematoxylin (Sigma, St. Louis, MO, USA), dehydrated, and mounted. Immunoperoxidase staining was performed with the automated Bio Tek-1000 immunostainer system (Bio Tek Solutions Inc., Santa Barbara, CA, USA). All procedures were performed according to the manufacturer's protocols. A Mel-CAM (CD146) polyclonal antibody 18 and an hPL monoclonal antibody were used for comparison with the staining pattern of HLA-G. The staining procedures for negative controls were the same except for the replacement of the primary antibody with a preimmunized mouse serum.
RESULTS
The immunostaining results of HLA-G in gestational trophoblastic lesions and a variety of uterine neoplasms are summarized in Table 1 . All trophoblastic lesions, including choriocarcinomas, placental site trophoblastic tumors, epithelioid trophoblastic tumors, placental site nodules, and exaggerated placental sites examined, demonstrated HLA-G immunoreactivity in at least 70% of cells. A total of 100% of implantation site IT cells in placental site trophoblastic tumors, like their normal counterparts in the implantation site and exaggerated placental site, showed strong membranous and cytoplasmic staining for HLA-G ( Figs. 1, 2) . The HLA-G immunostaining highlighted very different growth patterns of IT in placental site trophoblastic tumors and exaggerated placental sites, as also highlighted by Mel-CAM and hPL. In exaggerated placental site the IT cells infiltrate the endomyometrium as single cells or cords, often in a linear pattern, whereas in placental site trophoblastic tumors the cells form confluent masses (Figs. 1, 2). This feature can assist in the differential diagnosis of these lesions. In contrast to implantation site IT, the percentage of HLA-G-positive chorionic-type IT cells in the chorion laeve of the normal placenta ranged from 60% to 70%. Specifically, IT cells that contained eosinophilic cytoplasm were immunoreactive for HLA-G, but IT cells with clear cytoplasm were always negative ( Fig. 3 ). In epithelioid trophoblastic tumors, 70-100% of IT cells were positive for HLA-G ( Fig. 4 ) and in placental site nodules 70-90% of IT cells were positive for HLA-G ( Fig. 5 ). As in the chorion laeve, the HLA-G-positive IT cells in epithelioid trophoblastic tumors and placental site nodules were nearly always those with eosinophilic cytoplasm; the cells with clear cytoplasm were rarely positive. The immunostaining pattern of HLA-G was compared with hPL and Mel-CAM (CD146) in the placental site nodules. HLA-G was diffusely expressed in IT cells, whereas hPL and Mel-CAM expression was only focal (Fig. 5 ). The staining intensity of HLA-G in IT cells in placental site trophoblastic tumor and epithelioid trophoblastic tumor appeared to be comparable with normal IT cells. In choriocarcinoma HLA-G was localized in mononucleate cells but not in syncytiotrophoblast cells (Fig. 6A, B) . The HLA-G-positive cells were also immunoreactive to Mel-CAM, which is specifically expressed in IT cells in choriocarcinomas. 11 In contrast to IT cells, myometrial, endometrial, endothelial, and endometrial stromal cells as well as lymphocytes were negative for the HLA-G antibody. HLA-G immunoreactivity was not detected in any of the nontrophoblastic uterine neoplasms (Table 1) .
DISCUSSION
In this study HLA-G immunoreactivity was expressed in all gestational trophoblastic lesions, including exaggerated placental site, placental site nodule, placental site trophoblastic tumor, epithelioid trophoblastic tumor, and choriocarcinoma, but not in nontrophoblastic uterine tumors. The detailed distribution of HLA-G in a variety of tumors outside the female genital tract has been previously reported. 2, 7, 9 Briefly, the vast majority of these nontrophoblastic tumors fail to express HLA-G. 2, 9 Exceptions include melanoma, renal cell carcinoma, and large cell carcinoma of the lung, which in some cases demonstrate scattered focal immunostaining for HLA-G. 4, 6, 20 This restricted expression of HLA-G in extrauterine tumors together with our findings showing an absence of HLA-G immunoreactivity in nontrophoblastic uterine tumors and normal uterine tissues suggests that HLA-G can be a very useful marker in the diagnosis of trophoblastic tumors and tumor-like lesions.
In this study HLA-G immunoreactivity was identified in IT but not in cytotrophoblast and syncytiotrophoblast. Compared with other trophoblastic markers, HLA-G appears to be more sensitive and specific for IT. Tables 2  and 3 summarize the immunohistochemical findings of several antibodies in the different trophoblast subpopulations and related lesions. For example, ␤-hCG is exclusively expressed in syncytiotrophoblast and is useful in the diagnosis of choriocarcinoma, but in exaggerated placental sites, placental site nodules, placental site trophoblastic tumors, and epithelioid trophoblastic tumors, ␤-hCG expression is typically minimal or focal. Similarly, hPL is diffusely expressed in placental site trophoblastic tumors and exaggerated placental sites, but it is only focally (<10%) expressed in chorionic-type IT cells in placental site nodules and epithelioid trophoblastic tumors. Mel-CAM (CD146) is more sensitive than hPL as it is expressed in 100% of implantation site IT in exaggerated placental sites and placental site trophoblastic tumors but is only focally expressed in placental site nodules and epithelioid trophoblastic tumors. 11, 13, 17 PlAP lacks consistent staining in placental site nodules 10, 19 and is only weakly or not expressed in epithelioid trophoblastic tumors 13 and implantation site IT. 23 In contrast to these markers, HLA-G stains 70-100% of the IT cells in all of these lesions. HLA-G immunostaining, by highlighting the growth patterns of IT, can facilitate the distinction between a placental site trophoblastic tumor and an exaggerated placental site. In a placental site trophoblastic tumor the cells form confluent masses, whereas in an exaggerated placental site the IT cells infiltrate the endomyometrium as single cells and cords of cells. Other markers used in the differential diagnosis of trophoblastic lesions such as cytokeratin 18 and inhibin-␣ are expressed in a variety of other tumors besides trophoblastic lesions. 12, 13 Analysis of the HLA-G expression in the placenta and in trophoblastic lesions also sheds light on the pathogen- esis of trophoblastic neoplasms. The diffuse expression of HLA-G in the trophoblast of trophoblastic columns (Fig. 6C ) and the implantation site in all stages of placentation is consistent with the previous report 1 and supports the view that trophoblastic cells in the trophoblastic columns are a subpopulation of IT cells, not cytotrophoblast, as the latter are negative for HLA-G. Thus, although choriocarcinoma has been traditionally described as being composed of cytotrophoblast and syncytiotrophoblast, the presence of HLA-G, a specific marker of IT, in the vast majority of mononucleate cells in choriocarcinoma indicates that these cells are IT, not cytotrophoblast. This interpretation is supported by our previous study showing that the majority of cells in choriocarcinoma are positive for Mel-CAM, which is also expressed by IT but not cytotrophoblast. 11 The arrangement of trophoblastic cells in choriocarcinoma (Fig. 6A,  B ) bears a close resemblance to the arrangement of trophoblast in the trophoblastic columns (especially from complete hydatiform moles) with cytotrophoblast typically differentiating into IT (villous-type) and then syncytiotrophoblast. Besides, similar to choriocarcinoma, the IT cells in the trophoblastic columns of com-plete hydatidiform moles strongly and diffusely express HLA-G. 3, 8 Thus, we speculate that choriocarcinoma develops as a result of transformation of villous-type IT (in normal placenta or complete hydatidiform moles) that differentiates into syncytiotrophoblast. It is also conceivable that cytotrophoblast differentiates directly into syncytiotrophoblast, but the former pathway is more likely as choriocarcinomas contain only a small number of cytotrophoblastic cells. This pathway of differentiation for choriocarcinoma contrasts to that of placental site trophoblastic tumor in which villous-type IT differentiates into implantation site IT or in epithelioid trophoblastic tumor where villous-type IT differentiates into chorionic-type IT. 14 The distribution of HLA-G immunoreactivity in chorionic-type IT, as described in this study in conjunction with previous studies, 22 suggests that this type of trophoblast is comprised of two distinct cell populations, one with clear cytoplasm and one with eosinophilic cytoplasm. The finding that HLA-G immunoreactivity is confined to the chorionic-type IT cells with eosinophilic cytoplasm but is rarely detected in cells with clear cytoplasm is similar to our previous reports showing that Mel-CAM (CD 146) and hPL are most often localized in this IT subpopulation, although in a much lower percentage of cells. The same differential HLA-G expression is present in placental site nodules and epithelioid trophoblastic tumors, thus accounting for the variable proportion of HLA-G-positive IT cells in these lesions, and provides further support for the view that placental site nodule and epithelioid trophoblastic tumor are related to the IT cells in the chorion laeve 13, 17 (Table 3) .
Because trophoblastic lesions are gestational in origin, they contain paternal antigens and represent semiallografts to the patient. Recent advances in reproductive immunology have shed light on the molecular mechanisms underlying the immunologic tolerance of trophoblastic cells. Thus, it appears that the expression of HLA-G plays a role in the development of immunotolerance of IT cells. This could possibly account for the long latency periods that have been observed for choriocarcinoma and for other trophoblastic lesions derived from IT, such as placental site nodules and epithelioid trophoblastic tumors, which have been discovered many years after patients have had tubal ligations. 13, 15, 17, 24 In conclusion, we have shown that an HLA-G-specific antibody (4H84) specifically stains IT cells in normal placentas and trophoblastic lesions in paraffin sections. Although HLA-G appears to be an excellent marker for IT in trophoblastic lesions, it should be noted that rare metastatic tumors to the uterus may also express HLA-G, but the distribution is focal in contrast to the diffuse expression of HLA-G in trophoblastic lesions. Thus, this antibody can be used in combination with other antibodies, such as those that react with inhibin-␣ and CK18 in the differential diagnosis of gestational trophoblastic lesions from nontrophoblastic tumors. A combination of Mel-CAM, hPL, and Ki-67 can then be used to further distinguish among different trophoblastic lesions 16 ( Table 3) . ᮀ 
